Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? : Results from the Dyslipidemia International study II.

Autor: Gitt AK; Herzzentrum Ludwigshafen, Ludwigshafen, Germany. GittA@klilu.de.; Stiftung IHF-Institut für Herzinfarktforschung Ludwigshafen, Bremser Str. 79, 67117, Ludwigshafen, Germany. GittA@klilu.de., Rieber J; Klinikum Bogenhausen, Munich, Germany., Hambrecht R; Klinikum Links der Weser, Bremen, Germany., Brachmann J; Klinikum Coburg, Coburg, Germany., Graf K; Jüdisches Krankenhaus Berlin, Berlin, Germany., Horack M; Stiftung IHF-Institut für Herzinfarktforschung Ludwigshafen, Bremser Str. 79, 67117, Ludwigshafen, Germany., Karmann B; MSD SHARP & DOHME GmbH, Haar, Germany., Vyas A; School of Public Health, Department of Epidemiology, Rutgers University, Piscataway, NJ, USA.; College of Pharmacy, Department of Pharmacy Practice, University of Rhode Island, Kingston, RI, USA., Lautsch D; Merck & Co., Inc., Kenilworth, NJ, USA., Ambegaonkar B; Merck & Co., Inc., Kenilworth, NJ, USA., Brudi P; Merck & Co., Inc., Kenilworth, NJ, USA.
Jazyk: angličtina
Zdroj: Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2018 Dec; Vol. 130 (23-24), pp. 707-715. Date of Electronic Publication: 2018 Sep 03.
DOI: 10.1007/s00508-018-1375-3
Abstrakt: Objective: To document utilization of lipid-lowering therapy, attainment of low-density lipoprotein cholesterol target values, and cardiovascular outcomes in patients hospitalized for acute coronary syndrome in Germany.
Methods: The Dyslipidemia International Study II was a multicenter, observational study of the prevalence of dyslipidemia and lipid target value attainment in patients surviving any acute coronary syndrome event. Among patients on lipid-lowering therapy for ≥3 months, use of lipid-lowering therapy and lipid profiles were assessed at admission and again at 120 ± 15 days after admission (the follow-up time point). Multivariate logistic regression was used to identify variables predictive of low-density lipoprotein cholesterol target value attainment in patients using lipid-lowering therapy.
Results: A total of 461 patients hospitalized for acute coronary syndrome were identified, 270 (58.6%) of whom were on lipid-lowering therapy at admission. Among patients on lipid-lowering therapy, 90.7% and 85.9% were receiving statin monotherapy at admission and follow-up, respectively. Mean (SD) low-density lipoprotein cholesterol levels in patients on lipid-lowering therapy were 101 (40) mg/dl and 95 (30) mg/dl at admission and follow-up, respectively. In patients with data at both admission and follow-up (n = 61), low-density lipoprotein cholesterol target value attainment rates were the same (19.7%) at both time points. Smoking was associated with a 77% lower likelihood of attaining the low-density lipoprotein cholesterol target value.
Conclusion: Hospitalization for an acute event does not greatly alter lipid management in acute coronary syndrome patients in Germany. Both lipid-lowering therapy doses and rates of low-density lipoprotein cholesterol target value attainment remained essentially the same several months after the event.
Databáze: MEDLINE
Externí odkaz: